Beyond Cancer to Present Phase 1 Data on Nitric Oxide Therapy for Solid Tumors at AACR 2026
Event summary
- Beyond Cancer, a subsidiary of Beyond Air, will present Phase 1 trial data on intratumoral ultra-high concentration nitric oxide (UNO) for solid tumor metastases at the AACR Annual Meeting 2026.
- The presentation is scheduled for April 19, 2026, in San Diego, featuring data from a first-in-human study.
- Beyond Cancer is exploring UNO's potential as an immunotherapeutic and radiotherapy enhancer for solid tumors.
- The company is also conducting preclinical studies to inform additional treatment protocols.
The big picture
Beyond Cancer's presentation at AACR 2026 highlights the growing interest in nitric oxide as a potential immunotherapeutic for solid tumors. The company's proprietary delivery system for ultra-high concentration nitric oxide positions it uniquely in the oncology space, though it faces significant competition from established players. The success of this Phase 1 trial could validate the therapeutic potential of UNO and attract further investment or partnerships.
What we're watching
- Clinical Efficacy
- How the Phase 1 data will demonstrate the safety and efficacy of intratumoral UNO in solid tumor metastases.
- Regulatory Pathway
- Whether the positive data will accelerate regulatory approvals for Beyond Cancer's nitric oxide therapy.
- Market Positioning
- The pace at which Beyond Cancer can differentiate itself in the competitive oncology space.
Related topics